Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction

Journal of Cardiovascular Medicine

Volumn 16, Issue 6, 2015, Pages 438-443

  Aramburu Bodas, Óscar ^a   Garciá Casado, Beatriz ^b   Salamanca Bautista, Prado ^a   Guisado Espartero, Mariá E ^c   Arias Jiménez, José L ^a   Barco Sánchez, Antonio ^a   Santamariá González, Juan Carlos ^d   Formiga, Francesc ^e   Montero Pérez Barquero, Manuel ^f   Manzano, Luis ^g  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b Hospital Virgen de la Merced   (Spain)

^c HOSPITAL INFANTA MARGARITA   (Spain)

^d Hospital Nisa Aljarafe   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF CÓRDOBA   (Spain)

^g UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

biomarkers; heart failure; osteoprotegerin; preserved ejection fraction; reclassification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; OSTEOPROTEGERIN; UREA; BIOLOGICAL MARKER; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

ACUTE HEART FAILURE; AGED; ANEMIA; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; COMORBIDITY; CONTROLLED STUDY; DECOMPENSATED HEART FAILURE WITH PRESERVED EJECTION FRACTION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SURVIVAL; ACUTE DISEASE; BLOOD; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RANK LIGAND; RISK ASSESSMENT; STROKE VOLUME;

EID: 84929030138     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000229     Document Type: Article

References (26)

1. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5:618-625.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:2148-2159.
3. Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation 2003; 107:1460-1462.
4. Richards AM. What we may expect from biomarkers in heart failure. Heart Fail Clin 2009; 5:463-470.
5. Mogelvang R, Haahr-Pedersen S, Bjerre M, et al. Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013; 99:106-110.
6. Kielch S, Schett G, Wenning G, et al. Osteoproteregin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-2180.
7. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007; 49:1392-1398.
8. Nyrnes A, Njolstad I, Mathiesen EB, et al. Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromso study. Gend Med 2012; 9:536-547.
9. Fuernau G, Zaehringer S, Eitel I, et al. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2013; 167:2134-2139.
10. Røysland R, Masson S, Omland T, et al. Prognostic value of osteoproteregin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010; 160:286-293.
11. Ueland T, Dahl CP, Klekshus J, et al. Osteoproteregin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011; 4:145-152.
12. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic Heart Failure of the European Society of Cardiology. Eur J Heart Fail 2008; 10:933-989.
13. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculation to measure usefulness of new biomarkers. Stat Med 2011; 30:11-21.
14. Pedersen S, Mogelvang R, Bjerre M, et al. Osteoprotegerin predicts longterm outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012; 123:31-38.
15. Cąnga A, Durakoglugil ME, Erdogan T, et al. Elevated serum osteoprotegerin levels predict in-hospital major adverse cardiac events in patients with ST elevation myocardial infarction. J Cardiol 2012; 60:355-360.
16. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44:1970-1976.
17. Ueland T, Aukrust P, Dahl CP, et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med 2011; 270:452-460.
18. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation 2003; 107:346-354.
19. Lakatta EG, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am 2009; 93:583-604.
20. Borowiec A, Dabrowski R, Kowalik I, et al. Osteoprotegerin in patients with degenerative aortic stenosis and preserved left-ventricular ejection fraction. J Cardiovasc Med (Hagerstown) 2014 [Epub ahead of print].
21. Kudlacek S, Schneider B, Woloszczuk W, et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003; 32:681-686.
22. Osorio A, Ortega E, Torres JM, et al. Biochemical markers of vascular calcification in elderly hemodialysis patients. Mol Cell Biochem 2013; 374:21-27.
23. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172 [discussion 207-212].
24. Kalogeropoulos AP, Georgiopoulou VV, Butler J. Clinical adoption of prognostic biomarkers: the case of heart failure. Prog Cardiovasc Dis 2012; 55:3-13.
25. Jansson AM, Hartford M, Omland T, et al. Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2012; 32:3041-3049.
26. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated Creactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897-1908.